Genital Neoplasms, Male
16
2
4
4
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
37.5%
6 terminated out of 16 trials
40.0%
-46.5% vs benchmark
6%
1 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Health Gatherings - For Your Health After Cancer
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
Trial of NanoPac Focal Therapy for Prostate Cancer
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
Protection of Rectum From High Radiation Doses Using a Spacer
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma